NCT00003018
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
PHASE2
COMPLETED
NCT00003018
INTERVENTIONAL
A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
DISEASE CHARACTERISTICS: Histologically or cytologically proven stage II or III pancreatic adenocarcinoma Ductal adenocarcinoma Mucinous noncystic carcinoma Signet ring cell carcinoma Adenosquamous carcinoma Undifferentiated (anaplastic) carcinoma Mixed ductal-endocrine carcinoma Well differentiated adenocarcinoma Moderately well or poorly differentiated adenocarcinoma Undifferentiated ductal carcinoma Must have unresectable and localized disease Measurable or evaluable disease
PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception Loss of no greater than 15% of actual body weight Oral intake of greater than 1,200 calories per day No other malignancy within the past 5 years except adequately treated basal or squamous cell skin cancer, carcinoma in situ of the cervix, or any stage I or II cancer that is currently in complete remission
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic chemotherapy for pancreatic cancer Endocrine therapy: Not specified Radiotherapy: No prior radiation therapy for pancreatic cancer Surgery: At least 2 weeks since prior surgical bypass procedure and recovered
Pancreatic Cancer
- TREATMENT
-
- Type: DRUG
- Name: dipyridamole
- Description: 75mg/dose, PO, Days 1-28 of 5 week cycle
- Arm Group Labels: Chemotherapy
-
- Type: DRUG
- Name: fluorouracil
- Description: 200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle
- Arm Group Labels: Chemotherapy
-
- Type: DRUG
- Name: leucovorin calcium
- Description: 30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle
- Arm Group Labels: Chemotherapy
-
- Type: DRUG
- Name: mitomycin C
- Description: 10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
- Arm Group Labels: Chemotherapy
- SWOG Cancer Research Network